A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.

Sponsor
Innopeutics Corporation
Study ID
NCT07629115
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - 80 Years
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.

Key Dates

First listed
Jun 5, 2026
Start date
May 29, 2026
Status verified
Jun 2026
Primary completion
Jul 30, 2031
Completion
Oct 30, 2031

Study Design

Enrollment
6 participants (estimated)

Arms

  • Arm: The group that received IPS101A
    The group of subjects who received IPS101A in the IPS101A-10 clinical trial

Primary Outcome Measure

Safety Evaluation: Incidence of serious adverse events of special interest [ Time Frame: Baseline to 5 years ]

Central Contacts

Find similar trials

Nationwide
Parkinson's disease trialsNeurology trialsBrain disorders trials

Related Studies